Europe Ripe For Broader Biologic Use In Inflammatory Conditions
This article was originally published in Scrip
Executive Summary
The uptake in Europe of biosiomilar infliximab (versions of Janssen's blockbuster Remicade) for inflammatory diseases like rheumatoid arthritis and psoriasis has been patchy to date. In some countries of northern Europe, notably Norway, Denmark and the Netherlands, the biosimilar has been embraced and is capturing the large part of the infliximab market. In other parts of Europe, such as the UK, biosimilar developers report frustration at the lack of movement from the branded product.
